VERV - Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg

2024-05-09 09:32:14 ET

Summary

• Crispr Therapeutics AG reported a net loss of $116.6 million in Q1 2024, but is expected to have significant earnings in the future as its gene editing therapy Casgevy gains commercial sales.
• Casgevy is approved to treat Sickle Cell Disease and Transfusion Dependent Beta Thalassemia in the U.S., EU, and other territories, with the potential to "functionally cure" patients.
• Crispr Therapeutics has a strong balance sheet, a diverse pipeline, and the potential to expand its reach to a larger patient population in the future.
• Its three targets ex-Casgevy are Type 1 diabetes, immuno-oncology, and in-vivo gene therapy - some compelling progress is being made in each field.
• In short - what's not to like? One day, Crispr Therapeutics will get the valuation upgrade it deserves.

Investment Overview

Crispr Therapeutics AG ( CRSP ), the first company to secure U.S. approval for a CRISPR ("clustered, regularly interspaced, short palindromic repeats") based gene editing therapy, Casgevy, indicated for Sickle Cell Disease ("SCD") and Transfusion Dependent Beta Thalassemia ("TDT"), reported its Q1 2024 earnings yesterday after the bell.

The reality is that Crispr Therapeutics will have much more significant earnings quarters in the years ahead, as Casgevy - which was only approved for SCD in December last year, and for TDT in mid-January this year - begins to make meaningful commercial sales, and the company secures further drug approvals, which is what I'd expect to happen within the next two to three years....

For further details see: